Skip to main content
letter
. 2014 Dec;26(6):711–716. doi: 10.3978/j.issn.1000-9604.2014.12.03

Figure 1.

Figure 1

Reduced levels of serum miR-17 in GC compared to healthy control and BGD. qRT-PCR was performed to detect serum levels of miR-17 in 40 GC, 32 BGD and 36 healthy control samples. (A) The concentration of miR-17 was significantly lower in sera from both GC and BGD patients than in that from healthy individuals (P=0.000 and P=0.002, respectively). Serum levels of miR-17 were significantly lower in GC patients than in BGD patients (P=0.001). Serum levels in order of expression level were healthy control >BGD >GC; (B) ROC curve analysis reveals an AUC of 0.879 in discriminating GC patients from controls; (C) ROC curve analysis reveals an AUC of 0.717 in discriminating GC patients from BGD patients; (D) ROC curve analysis reveals an AUC of 0.725 in discriminating BGD patients from controls. GC, gastric cancer; BGD, benign gastric disease; qRT-PCR, quantitative reverse transcription polymerase chain reaction; ROC, receiver-operating characteristic; AUC, area under the curve.